www.dailypolitical.com ·
biote nasdaqbtmd announces quarterly earnings results misses estimates by 0 03 eps
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedBiote's earnings miss and revenue decline, driven by a recall in its procedure segment, indicate operational weakness. The company is a small-cap healthcare firm focused on hormone optimization and dietary supplements. The recall directly impacts procedure revenue and margins, while supplement growth provides partial offset. No broader sector or supply chain impact is evident; the event is company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Biote (NASDAQ:BTMD) reported Q1 2026 EPS of $0.06, missing consensus estimate of $0.09.
- Revenue was $44.94 million, below expected $46.02 million, down 8.3% YoY.
- Procedure revenue fell 13.2% to $31.3 million due to a $1.7 million recall.
- Dietary supplement sales increased 19.1% to $11 million.
- Stock traded down to $2.20, market cap $87.01 million.
Biote's hormone optimization procedures and stock are pressured down 2-5% within 48h due to earnings miss and recall.
Sign in to see all sector verdicts, full thesis and counter-argument debate.